31E9 (ATCC® HB-11052)

Organism: human (B cell); human (leukemia)  /  Cell Type: hybridoma: T lymphocyte  /  Disease: Allergen

Permits and Restrictions

View Permits

Organism human (B cell); human (leukemia)
Cell Type hybridoma: T lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1
Disease Allergen
Applications
The cells produce antigen specific GIF.
Derivation
Peripheral blood T cells from a patient allergic to Japanese cedar pollen were fused with BUC cells (HPRT - derivative of CEM cells).
Clinical Data
Peripheral blood T cells from a patient allergic to Japanese cedar pollen were fused with BUC cells (HPRT - derivative of CEM cells).
Genes Expressed
Japanese cedar pollen cryj-1 specific human glycosylation inhibiting factor (GIF)
Cellular Products
Japanese cedar pollen cryj-1 specific human glycosylation inhibiting factor (GIF)
Comments
Peripheral blood T cells from a patient allergic to Japanese cedar pollen were fused with BUC cells (HPRT - derivative of CEM cells).
The cells produce antigen specific GIF.
Cryj-1 is a 40000 dalton glycoprotein that constitutes the major allergen in Japanese cedar pollen.
Complete Growth Medium The base medium for this cell line is ATCC Hybri-Care Medium, Catalog No. 46-X. Hybri-Care Medium is supplied as a powder and should be reconstituted in 1 L cell culture grade water. To make the complete growth medium, add the following components to the base medium:
  • fetal bovine serum to a final concentration of 10%
  • 1.5 g/L sodium bicarbonate for use with 5% CO2 in air atmosphere.
  • Subculturing
    Medium Renewal: Every 2 to 3 days
    Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
    Name of Depositor La Jolla Institute for Allergy and Immunology
    References

    Ishizaka K. Suppressor T-cell hybridoma and production of allergen specific glycosylation inhibiting factor. US Patent 5,565,338 dated Oct 15 1996

    Ishizaka K. Antigen-specific human glycosylation inhibiting factor. US Patent 5,723,582 dated Mar 3 1998

    Notice: Necessary PermitsPermits

    These permits may be required for shipping this product:

    • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
    Basic Documentation
    References

    Ishizaka K. Suppressor T-cell hybridoma and production of allergen specific glycosylation inhibiting factor. US Patent 5,565,338 dated Oct 15 1996

    Ishizaka K. Antigen-specific human glycosylation inhibiting factor. US Patent 5,723,582 dated Mar 3 1998